三大徵兆，習近平全中！二十一大人事佈局加速；為何任澤平“唱響光明倫”也被禁言？

用邏輯和常識看世界，一個值得信賴的每天陪伴型頻道。 每天晚上7:00發佈（美東時間）。 00:00 中美两国财经舆论反思科技股大跌 美国市场反思：资金流动表明投资者更倾向于降低风险，优质股抗跌能力受到青睐 中国股市反思：知名股票评论员任泽平微信公众号遭限制，分析其被禁言的底层逻辑与替罪羊效应 12:40 马斯克星链（Starlink）的最新动态 乌克兰军用星链网络已恢复正常运行，速度限制解除 路透社独家报道指出，美国多届政府曾多次要求马斯克干预星链在乌克兰和中东地区的服务 17:50 癌症治疗领域的两项重要信息 安进（Amgen）联合阿斯利康（AstraZeneca）的免疫疗法，将侵袭性肺癌患者的死亡风险显著降低58% 澄清Moderna股价大跌原因，确认其癌症疫苗早前发布的研发成果依然有效且可信 24:11 金正恩访问中国丹东与中朝关系观察 金正恩跨越新鸭绿江大桥进入中国，标志中朝贸易关系升温及中共地缘政策的调整 24:47 中共五中全会前夕密集调整省级领导 多省主要负责人高频换班，分析指出这是中共提前为“二十一大”进行的人事卡位与筹备 27:25 中国社交网络热议奇文《王朝覆灭前三大特征》剖析 对照当今中国政治经济局势，逐一分析“管得多、财政紧、民心散”三大特征的具体体现 探讨中国知识分子“借古讽今”的传统，以及未能突破“保党保政权”的局限性政治逻辑 CNBC： Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca , a study found. Full results from a late-stage trial released Saturday show that adding Amgen’s immunotherapy Imdelltra to AstraZeneca’s Imfinzi drug slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer, a fast-growing disease that has spread beyond the lung where it began. The drug combination extended their median overall survival to 21.1 months compared with 12.7 months with AstraZeneca’s drug alone, the trial found. That means half of patients in the group that took the combination regimen were alive for at least roughly 21 months. The trial tested the combo as a maintenance therapy in patients who received initial treatment with Imfinzi and chemotherapy, and whose cancer had not progressed. “I think there are moments in medicine when you see a piece of data that is so profound that it’s going to transform the standard of care for patients, and I think, honestly, we’re at that moment,” said Dr. Paul Burton, Amgen’s chief medical officer, in an interview. The combination “has the potential to take on one of the most aggressive cancers that we deal with today, and almost convert it into a chronic disease,” he said, adding that “these data say that’s a possibility.”  The results also suggest a greater commercial opportunity for Imdelltra, which posted $288 million in sales during the second quarter, up 115% year over year. The drug already generated $627 million in global sales in 2025 and appears to be on its way to becoming a blockbuster medicine, or hitting the $1 billion sales threshold. Small cell lung cancer remains difficult to treat because, even if chemotherapy initially works well for most patients, the disease often returns or progresses within months, said lead trial investigator Dr. Jacob Sands, who is the associate chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute.  He said immunotherapy has helped a small subset of patients achieve years of disease control, but most have not experienced similarly durable benefits, highlighting the need for better treatments. There are roughly 31,000 new small cell lung cancer cases in the U.S. each year, and an estimated 60% to 70% of those people are diagnosed with extensive-stage disease. Sands said the benefits in the trial were seen across subgroups of patients, including those whose cancer spread to the brain or liver. Disease that has spread to those organs is associated with poorer treatment outcomes. He added that with longer-term follow-up data on the patients, the 21-month figure “may evolve further and hopefully will substantially improve,” similar to what Amgen saw in a Phase 1 trial on the immunotherapy combination. In that early-stage trial on a smaller number of patients, a long-term follow-up showed the benefit was sustained for years.  #股市 #習近平 #金正恩 #馬斯克 #烏克蘭